Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Pathological findings in Alport syndrome frequently show mesangial proliferation and sometimes incidental IgA deposition, in addition to unique glomerular basement membrane (GBM) changes including thin basement membrane and/or lamellation. However, similar GBM abnormalities are also often observed in IgA nephropathy. Both diseases are also known to show hematuria, proteinuria, and sometimes macrohematuria when associated with viral infection. Therefore, it can be difficult to make a differential diagnosis, even based on clinical and pathological findings. Some recent articles demonstrated that galactose-deficient IgA1 (Gd-IgA1)-specific monoclonal antibody (KM55) could potentially enable incidental IgA deposition to be distinguished from IgA nephropathy.

Methods: We performed comprehensive gene screening and glomerular Gd-IgA1 and type IV collagen α5 chain immunostaining for five cases with both IgA deposition and GBM changes to confirm that Gd-IgA1 can help to distinguish these two diseases.

Results: Four of the cases were genetically diagnosed with Alport syndrome (Cases 1-4) and one was IgA nephropathy with massive GBM changes, which had a negative gene test result (Case 5). In Cases 1-4, glomerular Gd-IgA1 deposition was not detected, although there was positivity for IgA in the mesangial area. In Case 5, glomerular Gd-IgA1 deposition was observed.

Conclusion: Gd-IgA1 expression analysis could clearly differentiate these two disorders. This approach can be applied to identify these two diseases showing identical clinical and pathological findings.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10157-021-02054-3DOI Listing

Publication Analysis

Top Keywords

glomerular gd-iga1
16
iga nephropathy
12
alport syndrome
12
pathological findings
12
iga deposition
12
gbm changes
12
iga
8
cases iga
8
incidental iga
8
basement membrane
8

Similar Publications

Differential Expression of ATP6V1D and Its Diagnostic Potential in IgA Nephropathy.

Curr Med Sci

September 2025

Department of Agriculture and Biotechnology, Hunan University of Humanities, Science and Technology, Loudi, 417000, China.

Objective: IgA nephropathy (IgAN) is the most prevalent form of primary glomerular disease. However, its diagnosis is contingent on kidney biopsy. Therefore, noninvasive biomarkers are urgently needed for diagnosis.

View Article and Find Full Text PDF

IgA nephropathy (IgAN) is a prevalent primary glomerular disease and a major contributor to end-stage renal disease (ESRD). Budesonide Enteric Capsules (Nefecon®) are the first treatment approved by the U.S.

View Article and Find Full Text PDF

Abnormal galactosylation of IgA is a core factor in the development of IgA nephropathy (IgAN). Suppressor of cytokine signaling 1 (SOCS1) expression negatively correlates with IgA1 secretion in IgAN patients and that TLR9/MyD88 promotes aberrantly glycosylated IgA formation. Therefore, the present study exposed whether SOCS1 is involved in aberrant galactosylation of IgA in IgAN by regulating the TLR9/MyD88 signaling pathway through in vivo and in vitro experiments.

View Article and Find Full Text PDF

Predictive value of Gd-IgA1, poly-IgA in the treatment of IgA nephropathy with targeted-release formulation budesonide.

Clin Kidney J

July 2025

Renal Division, Department of Medicine, Peking University First Hospital, Beijing China; Institute of Nephrology, Peking University, Beiling, China; Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking

Background: Targeted release formulation (TRF) budesonide (Nefecon), targeting galactose-deficient immunoglobulin A1 (Gd-IgA1) production and IgA immune complex formation, has been approved for IgA nephropathy (IgAN) treatment. In this study we explored whether early changes in these biomarkers can predict the clinical response to Nefecon therapy.

Methods: Plasma samples from 27 IgAN patients treated with Nefecon and followed at least 6 months were collected during routine visits.

View Article and Find Full Text PDF

Lysosome-mediated aggregation of galactose-deficient IgA1 with transferrin receptor 1 links to IgA nephropathy.

Nat Commun

July 2025

Department of Nephrology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.

The retention of galactose-deficient IgA1 (Gd-IgA1) in the mesangium is central to IgA nephropathy (IgAN), but its intracellular fate remains unclear. Here, we show that transferrin receptor 1 (TfR1) mediates Gd-IgA1 uptake into mesangial cell lysosomes, where it forms non-digestible aggregates, disrupts lysosomal function, and triggers inflammatory responses. In renal biopsies from IgAN patients, IgA1 aggregates co-localize with TfR1 within lysosomes.

View Article and Find Full Text PDF